Search bioRxiv⌕ Search

bioRxiv · 10.1101/389726

Cathelicidin senses enteric pathogen Salmonella typhimurium/LPS for colonic chemokine generation: a new innate immune role for a host defense peptide

Abstract

The mechanisms by which epithelia identify and respond to pathogens are manifold, nuanced and complex. Here, using human-colon derived HT29 epithelial cells, mouse and human primary colonoids, and cathelicidin null (Cramp) mice, we report a novel immunoregulatory role for the antimicrobial peptide, cathelicidin, that was found to recognize and synergise with Salmonella typhimurium or its derived virulence factor lipopolysaccharide (LPS) to promote epithelial synthesis of the chemokine IL-8/KC for neutrophil recruitment/activation during infectious colitis. Mechanistically, cathelicidin facilitated the internalization of LPS via GM1 lipid rafts and subsequent TLR4 activation to promote IL-8 production. Furthermore, IL-8 output required the integrated activity of two signal transduction pathways: NF-{kappa}B and MEK 1/2 kinase signaling was required for IL-8 mRNA synthesis, while Src-EGFR-p38MAPK (NF-{kappa}B independent) activity underlay IL-8 mRNA stabilization. This immunomodulatory function of cathelicidin was key in colon defense, since Cramp-/- mice infected with a natural murine Gram negative intestinal pathogen, Citrobacter rodentium, displayed diminished KC secretion, impaired mobilization and reduced clearance of the bacteria. Occurring at concentrations lower than those necessary for anti-microbial activity, cathelicidins capacity to sense pathogens/LPS and enhance neutrophil recruitment reveals a novel function for this peptide in directing innate immunity which may be of pivotal importance in the control of infections colitis.\n\nAuthor summaryThe gut lining has a well regulated immune system that tolerates resident bacteria and does not respond to them. However, when pathogenic bacteria enter, there needs to be a protective response. How the gut lining switches from passive to protective is of interest. In our study, we determined host defense cathelicidin peptide (either naturally occurring or administered) \"instructs\" the colon lining to produce a compound (IL-8) that attracts white blood cells in response to a pathogen (Salmonella typhimurium) or lipopolysaccharide, a component of this pathogens cell wall. We discovered a novel mechanism by which cathelicidin facilitates uptake of lipopolysaccharide by the lining of the colon and how it activates receptors to increase synthesis and release of IL-8. In addition, we also detected a synergistic action between cathelicidin and intestinal pathogens in laboratory cultures of colon tissues from mice and humans, as well as in a mouse model of colitis with another pathogenic bacterium. Cathelicidin induced production of IL-8 which attracted and stimulated more white blood cells. Therefore, in addition to potential direct actions to supress harmful bacteria, cathelicidin also acts as a biological sensor in the gut lining, recognizing pathogens or factors they produce and increasing white cell responses.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Cobo, E. R., Holani, R., Lopes, F., Blyth, G. A. D., Jijon, H., McKay, D. M., Hollenberg, M. D.. 2018-08-10. Cathelicidin senses enteric pathogen Salmonella typhimurium/LPS for colonic chemokine generation: a new innate immune role for a host defense peptide. https://doi.org/10.1101/389726

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

CD19-CAR T-cell therapy resets the EBV+ autoreactive B cell repertoire in autoimmune disease

Epstein-Barr virus (EBV) reprograms autoreactive B cells into activated antigen-presenting cells that drive pathogenic T- and B-cell responses in autoimmune disease. Using EBV B-cell sequencing (EBV-seq), we profiled EBV+ B cells in patients treated with CD19 chimeric antigen receptor (CAR) T cells (systemic lupus, n=6; idiopathic inflammatory myopathies, n=3; systemic sclerosis, n=3) or rituximab (n=15). CAR T cells, but not rituximab, depleted EBV+ B cells, resetting the repertoire toward a naive state: predominantly IgM+ with minimal somatic hypermutation. Post-rituximab B-cells remained class-switched, hypermutated, and activated. Monoclonal antibodies cloned from EBV+ B cells lost autoreactivity after CAR T cells but not rituximab. Sustained drug-free remission occurred in 8/12 CAR-treated but 0/15 rituximab-treated patients. EBV+ B cells were predominantly Latency III and resisted anti-CD20 and anti-CD19 antibodies, yet were killed by CAR T cells and T-cell engagers. CD19-CAR T-cell therapy resets the autoreactive EBV+ B-cell repertoire, which may underlie sustained drug-free remission.

immunology↗

A minimal two-residue C-terminal truncation of AID in adult-onset hyper-IgM syndrome type 2 (HIGM2)

Activation-induced cytidine deaminase (AID), encoded by AICDA, facilitates class-switch recombination (CSR) and somatic hypermutation (SHM) in activated B cells. Loss of AID function causes hyper-IgM syndrome type 2 (HIGM2). While typically autosomal recessive, three C-terminal truncation variants have been reported to act in autosomal dominant manner. We describe a novel heterozygous AICDA nonsense variant, c.589G>T (p.G197*), that truncates the final two C-terminal residues of AID and results in adult-onset HIGM2. Single-cell sequencing of primary patient B cells revealed a complete block in CSR and a [~]10-fold reduction in SHM. AICDA mRNA expression was balanced between wild-type and variant alleles, yet AID protein abundance was reduced to [~]56% with normal subcellular localization. Remarkably, inducible germinal center (iGB) cultures restored CSR in purified naive patient B cells. CRISPR-Cas9 editing of healthy donor B cells confirmed that the iGB platform can rescue B cells harboring heterozygous, but not homozygous, AICDA variants. These results demonstrate that even a two-amino-acid truncation at the AID C-terminus is sufficient to disrupt its function and cause HIGM2.

immunology↗

Defining the Functional Consequence of the Human Ocular Microbiome

The ocular surface is one of the body's most environmentally exposed mucosal barriers, yet it is considered low biomass and harbors orders of magnitude fewer bacteria than microbe-rich sites like the gut. This has cast doubt on whether a functional core ocular microbiome exists at all. Having previously defined a protective gd T cell and IL-17 axis engaged by the murine commensal Corynebacterium mastitidis, we asked whether human-derived bacteria could do the same. Pairing sequencing and culturomics of healthy human conjunctiva from two geographically distinct cohorts, we define a stable core microbiome and identify Corynebacterium bovis as a consistent eye-resident commensal rather than a transient contaminant. In humans, C. bovis elicits a non-pathogenic response marked by IL-17 secretion by {gamma}{delta} T cells and circulating C. bovis-specific IgG, which suggests commensalism rather than pathology. Colonizing mice with human C. bovis strains from Pittsburgh or Miami reproduced this program and conferred protection against ocular infection with Staphylococcus aureus. Together, these findings identify C. bovis as a human-derived ocular commensal that can drive protective {gamma}{delta} T cell immunity, translating a mechanism previously defined only in mice into human relevance and a rational target against sight-threatening infection.

immunology↗